Inhibition of growth and reduction in tumorigenicity of UCI-107 ovarian cancer by antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide

By Chatzistamou Ioulia   Schally Andrew   Varga Jozsef   Groot Kate   Armatis Patricia   Bajo Ana  

Journal of Cancer Research and Clinical Oncology, Vol. 127, Iss. 11, 2001-11 ,pp. : 645-652

Springer Publishing Company

Access to resources Recommend Favorite

Vasoactive intestinal peptide represses activation of tumor-associated macrophages in gastric cancer via regulation of TNFα, IL-6, IL-12 and iNOS

By              

International Journal of Oncology, Vol. 47, Iss. 4, 2015-01 ,pp. : 1361-1370

Spandidos Publications

Access to resources Recommend Favorite

Endothelin Receptor Antagonists in Cancer Therapy

By Lalich Mihailo   McNeel Douglas   Wilding George   Liu Glenn  

Cancer Investigation, Vol. 25, Iss. 8, 2007-10 ,pp. : 785-794

Informa Healthcare

Access to resources Recommend Favorite

Vasoactive intestinal peptide induces CD14+HLA-DR/low myeloid-derived suppressor cells in gastric cancer

By                        

Molecular Medicine Reports, Vol. 12, Iss. 1, 2015-01 ,pp. : 760-768

Spandidos Publications

Access to resources Recommend Favorite

Vasoactive intestinal peptide receptor-based imaging and treatment of tumors (Review)

By          

International Journal of Oncology, Vol. 44, Iss. 4, 2014-01 ,pp. : 1023-1031

Spandidos Publications

Access to resources Recommend Favorite